Toshitha Kannan

Apr 1, 2024 | nature.com | Wei Zhou |Yuan Qi |Toshitha Kannan |Hiroaki Tateno |Daniel T. Claiborne |Mohamed Abdel-Mohsen

AbstractAberrant glycosylation is a crucial strategy employed by cancer cells to evade cellular immunity. However, it’s unclear whether homologous recombination (HR) status-dependent glycosylation can be therapeutically explored. Here, we show that the inhibition of branched N-glycans sensitizes HR-proficient, but not HR-deficient, epithelial ovarian cancers (EOCs) to immune checkpoint blockade (ICB).